Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

mace the Laperwork Reduction Act of 1999, no persons are required to	o respond to a confection of information unit	ess it contains a valid Olvid contr	number
Substitute for form 1449A/PTO	COM	IPLETE IF KNOWN	
OIPE	Application Number	09/692,634	우
NFORMATION DISCLOSURE	Confirmation Number	8314	
TATEMENT BY APPLICANT	Filing Date	October 19, 2000	m A
MAY 1 5 2001 (use as many sheets as necessary)	First Named Inventor	Paul John Rennie	
	Group Art Unit	1653	<del></del>
	Examiner Name		
of 3	Attorney Docket Number	8308	800

EXAMINER INITIALS*	Cite No. <sup>1</sup>	U.S. PATENT DOCUMEN Number Kind C	code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
7	1	4,444,885		Nakanishi et al.	4/24/1984	
1	2	4,552,899		Sunshine et al.	11/12/1985	
	3	4,619,934		Sunshine et al.	10/28/1986	
	4	4,689,223		Arias	8/25/1987	
	5	4,767,788		Diana	8/30/1988	
	6	4,826,683		Bates	5/02/1989	
	7	4,828,912		Hossain et al.	5/09/1989	
	8	4,897,304		Hossain et al.	1/30/1990	
	9	4,940,728		Postley	7/10/1990	
	10	4,956,385		Eby, III	9/11/1990	
	11	RE 33,465		Eby, III	11/27/1990	
	12	5,158,761		Kamishita et al.	10/27/1992	
	13	5,215,739		Kamishita et al.	6/01/1993	
	14	5,240,694		Gwaltney, Jr.	8/31/1993	
	15	5,252,318		Joshi et al.	10/12/1993	
-	16	5,409,905		Eby, III	4/25/1995	
T I	17	5,422,097		Gwaltney, Jr.	6/6/1995	
	18	5,466,680		Rudy	11/14/1995	
	19	5,492,689		Gwaltney, Jr.	2/20/1996	
	20	5,508,282		Tulin-Silver et al.	4/16/1996	
	21	5,599,534		Himmelstein et al.	2/4/1997	
	22	5,622,724		Bryce-Smith	4/22/1997	
	23	5,626,831		Van Moerkerken	5/6/1997	
	24	5,897,872		Picciano	4/27/1999	
	25	6,013,632		Jones et al.	1/11/2000	
	26	6,080,783		Davidson et al.	6/27/2000	
	27	6,187,332 B	31	Gern et al.	2/13/2001	

# **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOF Office <sup>3</sup>	REIGN PATENT I Number <sup>4</sup>	OOCUMENT Kind Co (if know		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
EXAMINER INITIALS*	Cite No. <sup>1</sup>					page(s), volume-issue num	riate), title of the item (book, ber(s), publisher, city and/or	T°
					/			

**EXAMINER** 

**DATE CONSIDERED** 

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	COM	IPLETE IF KNOWN	Ħ		
SIRA	Application Number	09/692,634	$\overline{c}$		-
O I E INFORMATION DISCLOSURE	Confirmation Number	8314	工		-
YATEMENT BY APPLICANT	Filing Date	October 19, 2000	m	3	7
MAY 1 5 2000 (ase as many sheets as necessary)	First Named Inventor	Paul John Rennie	$\overline{z}$	$\overline{}$	
	Group Art Unit	1653	m,	2	
k S	Examiner Name		<del></del>	<del> </del>	
SHEET 2 of 3	Attorney Docket Number	8308	6	2(	Å
RADEMA			Ō	0	$\overline{\Box}$

ı		9	$D^{A}$	TEI	NT	DOCI	IMENTS	
	•					1 /1 /1		

EXAMINER INITIALS*	Cite No. <sup>1</sup>	U.S. PATENT DOCUMENT Number Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Liftes Where Relevant Passages or Relevant Figures Appear
				·:	

# **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FO Office <sup>3</sup>	Number <sup>4</sup>	JMENT Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T⁵
	28	EP	0046409	A1	Walliczek	2/24/1982		
	29	DE	3431727 -	, A1	Hempel	3/13/1986		
	30	EP	0310317	A2	Bordt et al.	4/5/1989		
	31	EP	0371421	A2	Sehm	6/6/1990		
	32	EP	0408330 🗸	A2	Masterson	1/16/1991		
	33	EP	0856316 🗸	A1	Sawa	8/5/1998		
	34	wo	92/20352 🗸	A1	Budorov et al.	11/26/1992		X
	35	wo	99/44622 🗸	A1	Ormerod et al.	9/10/1999		
1	36	wo	94/22428 ~	A1	Morrey et al.	10/13/1994		
	37	EP	0505374 🗸	B1	Deihl	4/23/1997		

# OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T⁵

EXAMINER DATE CONSIDERED 6/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	COM	IPLETE IF KNOWN
OIPE	Application Number	09/692,634
NFORMATION DISCLOSURE	Confirmation Number	8314
ATATEMENT BY APPLICANT	Filing Date	October 19, 2000
MAY 1 5 2001 (use as many sheets as necessary)	First Named Inventor	Paul John Rennie
\ <b>1</b>	Group Art Unit	1653
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Examiner Name	
OF 3	Attorney Docket Number	8308

# **U. S. PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	U.S. PATEN Number	NT DOCUMENT  Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		l				!

# **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOR Office <sup>3</sup>	EIGN PATENT D Number <sup>4</sup>	OCUMENT Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
					-			

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T⁵
	38	GWALTNEY, Jr., "Upper Respiratory Infections –The Common Cold", Principles and Practices of	
		Infectious Diseases, 3 <sup>rd</sup> Edition, Published by Chruchill Livingstone, Section B, No. 42, pp. 489-493,	
	l	1990.	
	; /39	DOUGLAS et al., "Prophylactic Efficacy of Intranasal Alpha <sub>2</sub> -Interferon Against Rhinovirus Infections	
		in the Family Setting", The New England Journal of Medicine, Vol. 314, No. 2, pp. 65-70 (1/9/1986).	
	40	HIGGINS et al., "A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus	
	1	infections in human volunteers", Antiviral Research, Vol. 14, pp. 339-344 (1990).	
	41	FARR et al., "A Randomized Controlled Trial of Glucocorticoid Prophylaxis against Experimental	
		Rhinovirus Infection", The J. of Infectious Diseases, Vol. 162, pp. 1173-1177, (1990).	
	/42	BARROW et al., "The effect of intranasal nedocromil sodium on viral upper respiratory tract infections	
	1	in human volunteers", Clinical and Experimental Allergy, Vol. 20, pp. 45-51 (1990).	
	, 43	GWALTNEY, Jr., "Combined Antiviral and Antimediator Treatment of Rhrinovirus Colds", The J. of	
		Infectious Diseases, Vol. 166, 776-782 (1992).	
	44	POTTER et al., "Dias Rounds: Zinc Lozenges for Treatment of Common Colds", The Annals of	:
		Pharmacotherapy, Vol. 27, pp. 589-592 (1993).	
	45	ELLIOT, "Influenza Prevention and Treatment – An Update", The Pharmaceutical J., Vol. 265, pp.	1
	<u> </u>	446-451 (9/23/2000).	
1	146	BELSHE et al., "Genetic Basis of Resistance of Rimantadine Emerging during Treatment of Influenza	
	ľ	Virus Infection", J. of Virology, pp 1508-1512 (5/1988).	
	4.7	HAY, "The action of adamantanamines against influenza a viruses: inhibition of the M2 ion channel	l
		protein", <u>Virology</u> , Vol. 3, pp. 21-30 (1992).	
	48	MONTO et al., "Zanamivir in the prevention of influenza among healthy adults", JAMA, Vol 282, No.	
		1, pp. 31-35 (7/7/1999).	
1	49	Treanor et al., "Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute	
		Influenza", <u>JAMA</u> , Vol. 283, No. 8, pp. 1016-1024 (2/23/2000).	
4	50	HUGHES et al., "Acid Lability of Rhinovirus Type 14: Effect of pH, Time, and Temperature", Proc.	
		Soc. Exp. Eiol. Med., pp. 555-560 (1998).	
EXAMINER	!	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.